MedTrace Logo

Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough

NCT05120934 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-01-21

No results posted yet for this study

Summary

This research study is evaluating the effectiveness of escalating doses of Amitriptyline and Duloxetine in reducing cough frequency in patients with interstitial lung disease (ILD)-related cough.

Conditions

Interventions

DRUG

Amitriptyline 25 MG

25 mg orally for 4 weeks

DRUG

Amitriptyline 50 MG

50 mg orally for 4 weeks

DRUG

Duloxetine 30 MG

30mg orally for 4 weeks

DRUG

Duloxetine 60 MG

60mg orally for 4 weeks

DRUG

Placebo 30 MG

30mg tablet with no active study ingredient for 4 weeks

DRUG

Placebo 60 MG

60mg tablet with no active study ingredient for 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Vivek N Iyer, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2026-10-31
Completion
2026-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05120934 on ClinicalTrials.gov